Blue Cross Blue Shield of Massachusetts believes its newly inked provider pact with Caritas Christi Health Care — a community-based hospital network in New England with a network of 1,100 physicians that cares for about 60,000 members — will help bury the industry’s fee-for-service payment model.

In a nutshell, the payment plan — dubbed an alternative quality contract — combines a fixed payment per patient based on age, sex, and health status with an incentive payment earned for the quality and effectiveness of the care provided. This is the plan’s eighth AQC deal, which arrives as Massachusetts hosts a fierce debate over whether the traditional fee-for-service approach to paying providers should be axed. And while it may sound a lot like capitation, that’s not a word anyone at the health plan likes to bandy around.

The AQC plan is similar to a capitation agreement in that it establishes a per-member, per-month payment. But Deb Devaux, executive director of community transformation for the insurer, is careful to highlight some significant differences from a payment method that sparks bitter memories among providers from when it was tried in the ’90s.

“Capitation wasn’t funded adequately,” she says. With this new plan, the managed care organization worked with Caritas to establish the track record on health care costs for their patients, looking back over previous claims to come up with a reasonable idea of what the annual fee should be.

But the BCBS plan is intending to rein in costs by reducing waste and poor utilization. So the providers’ rates will rise at a sharply lower pace than the blistering 8 percent to 10 percent annual pace the plan has been experiencing for several years.

“These contracts are structured so that providers’ rates don’t rise so sharply, and the employer gets the benefit,” says Devaux. “We targeted about 2 percent [over inflation] and we want to fall in line with inflation, which has been 3 percent to 4 percent up to now.”

While about 20 percent of providers in Massachusetts have switched to global payment, many physicians continue to mount fierce resistance. In particular, the state medical association says that only big provider groups with a large patient base have the revenue and sophisticated information technology needed to successfully pull it off. Small practices just can’t do it.

But Devaux notes that the new BCBS pact with Caritas includes small physician practices that are part of a larger association, offering one model that other small practices might follow. Sticking with the current system, Devaux adds, is not an option.


Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.